Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer - Full Text View

Sponsor:	Radiation Therapy Oncology Group
Collaborator:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00006360

Purpose

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients who have stage II or stage III oropharyngeal cancer.

Condition	Intervention	Phase
Head and Neck Cancer Radiation Toxicity	Drug: radioprotection Radiation: radiation therapy	Phase I Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Head and Neck Cancer

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Acute salivary gland toxicity [ Designated as safety issue: Yes ]
Locoregional control [ Designated as safety issue: No ]
Whole mouth saliva output relative to pre-radiotherapy measurements [ Designated as safety issue: No ]
Acute mucositosis and other acute and late toxicities [ Designated as safety issue: Yes ]

Study Start Date:	February 2001
Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

Assess target coverage and major salivary gland sparing in patients with stage II or III oropharyngeal cancer treated with intensity-modulated radiotherapy.
Determine the nature and prevalence of acute and late side effects of this treatment in these patients.
Determine the rate and pattern of locoregional tumor recurrence in these patients after this treatment.

OUTLINE: This is a multicenter study.

Patients receive 3-D conformal radiotherapy and/or intensity-modulated radiotherapy daily 5 days a week for 6 weeks, in an effort to spare major salivary glands.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 57-64 patients will be accrued for this study over 27 months.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically proven stage II or III (T1-T2, N0-N1) squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or palate)
- Lymph nodes in both sides of neck at risk of metastatic disease and require radiotherapy
- Patients upstaged by imaging to N2 are eligible
Measurable or evaluable disease
- Greater than 1 cm in one dimension or with necrotic regions if by CT or MRI scan
Surgery of the primary tumor or lymph nodes limited to incisional or excisional biopsies
No distant metastases

PATIENT CHARACTERISTICS:

Age:

Over 18

Performance status:

Zubrod 0-1

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

No active untreated infection
No other malignancy within the past 5 years except nonmelanoma skin cancer or a carcinoma not of head or neck origin
No concurrent major medical or psychiatric illness that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

More than 3 months since prior chemotherapy
No concurrent chemotherapy

Endocrine therapy:

Not specified

Radiotherapy:

No prior head or neck radiotherapy

Surgery:

See Disease Characteristics

Other:

No other concurrent treatment for head and neck cancer
No prophylactic amifostine or pilocarpine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006360

Locations

United States, Arizona
Foundation for Cancer Research and Education
Phoenix, Arizona, United States, 85013
United States, California
UCSF Comprehensive Cancer Center
San Francisco, California, United States, 94115
United States, Florida
University of Florida Shands Cancer Center
Gainesville, Florida, United States, 32610-0385
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109-0010
United States, Missouri
CCOP - Kansas City
Kansas City, Missouri, United States, 64131
United States, New Jersey
Monmouth Medical Center
Long Branch, New Jersey, United States, 07740-6395
Community Regional Cancer Center at Community Medical Center
Toms River, New Jersey, United States, 08755
United States, Pennsylvania
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, United States, 19107-5541
United States, Texas
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, United States, 77030-4009
United States, Utah
Dixie Regional Medical Center
Saint George, Utah, United States, 84770
LDS Hospital
Salt Lake City, Utah, United States, 84143
United States, Vermont
Community Cancer Center at Rutland Regional Medical Center
Rutland, Vermont, United States, 05701
United States, Wisconsin
CCOP - Marshfield Clinic Research Foundation
Marshfield, Wisconsin, United States, 54449
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States, 53226
All Saints Cancer Center at All Saints Healthcare
Racine, Wisconsin, United States, 53405
Canada, Alberta
Stollery Children's Hospital at University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2R7
Canada, Quebec
McGill Cancer Centre at McGill University
Montreal, Quebec, Canada, H2W 1S6
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2L 4MI

Sponsors and Collaborators

Radiation Therapy Oncology Group

National Cancer Institute (NCI)

Investigators

Study Chair:

Avraham Eisbruch, MD

University of Michigan Cancer Center

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications:

Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR, Ang KK. Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2009 Jun 17; [Epub ahead of print]

Eisbruch A, Harris J, Garden A, et al.: Phase II multi-institutional study of IMRT for oropharyngeal cancer (RTOG 00-22): early results. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-79, S46-7, 2006.

Ploquin N, Lau H, Dunscombe P. Intensity modulated and three-dimensional conformal radiation therapy plans for oropharyngeal cancer: a comparison of their sensitivity to set-up errors and uncertainties. Curr Oncol. 2006 Apr;13(2):61-6.

ClinicalTrials.gov Identifier:	NCT00006360 History of Changes
Other Study ID Numbers:	CDR0000068231, RTOG-0022, RTOG-H-0022, RTOG-DEV-1065
Study First Received:	October 4, 2000
Last Updated:	March 25, 2010
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

stage II squamous cell carcinoma of the oropharynx
stage III squamous cell carcinoma of the oropharynx
radiation toxicity

Additional relevant MeSH terms:

Head and Neck Neoplasms
Oropharyngeal Neoplasms
Radiation Injuries
Neoplasms by Site
Neoplasms
Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Wounds and Injuries

ClinicalTrials.gov processed this record on February 09, 2012